Accretion Pharmaceuticals IPO — Listing Performance
Accretion Pharmaceuticals IPO facts & figures
| Issue category | SME |
|---|---|
| Issue open date | 14 May 2025 |
| Listing date | 21 May 2025 |
| Overall subscription | 7.32x |
| Issue price | ₹101 |
| Listing-day close | ₹82.95 (-17.87%) |
| Recent market price | ₹215 (112.87% vs issue) |
| 52-week range | ₹54.60 – ₹210 |
| Identifiers | NSE: ACCPL · ISIN: INE0T8T01010 |
How the listing went
Accretion Pharmaceuticals listed at a discount, closing its first day 17.87% below the issue price, on moderate subscription of 7.32x.
Accretion Pharmaceuticals against every other debut on record
- Rank in 2025: 199 of 215 NSE debuts, on a -17.87% first-day close.
- 10th percentile of 116 SME debuts in 2025 (median 6.52%).
- 7th of 8 debuts in May 2025.
- Subscribed 7.32x: 46th percentile of 165 SME issues with a figure; the 32 subscribed between 5 and 20 times closed day one a median 7.66%.
- Opened 21.78% below issue, then added 3.91 points to the close.
- Day-one range ₹75.05 to ₹82.95: a 7.82% swing on the issue price.
- Last close ₹215 (11 Sep 2026): 112.87% above issue, against -17.87% on day one.
- 1% up its 52-week range of ₹54.60 to ₹210.
- Priced at the top of the ₹96 to ₹101 band.
- Listed 5 calendar days after close.
- All 601 SME debuts on record: median 14.22%, 79% closed above issue.
Computed over 1109 verified NSE debuts to 11 Sep 2026 · sources